Key Takeaway

• Vertical Integration: McKesson already has experience in clinical care delivery through its acquisition of US Oncology in 2010 and its Canadian INVIVA infusion network. The Option Care acquisition expands its presence in U.S. home and alternate-site infusion services.

• Distribution vs. Care Delivery: Infusion services require nursing infrastructure, clinical operations, and patient access beyond pharmaceutical distribution. Execution risks remain in managing patient referrals and treatment administration.

• Private Equity(PE) Opportunity: CD&R’s investment points to continued PE interest in established healthcare services companies trading at discounted valuations

Strategic Rationale - McKesson

• Expand Specialty Infusion Services: Gain access to a national home and alternate-site infusion network serving over 315,000 patients across all 50 states, supported by more than 5,000 clinicians and established hospital, physician, and payer relationships.

• Broaden Specialty Care Capabilities: Expand into complex therapies for autoimmune, neurological, and rare diseases while supporting the shift from hospitals to lower-cost home and community-based care.

• Capture Commercial Synergies: Leverage McKesson’s purchasing power, pharmaceutical distribution infrastructure, and manufacturer relationships to improve drug procurement and support new specialty therapies. Evercore estimates $1.0–$1.5B in potential incremental distribution revenue and $10–$30M in adjusted operating income.

• Establish a Path to Full Ownership: Secure a framework to acquire CD&R’s remaining stake, subject to specified conditions and regulatory approvals.

Strategic Rationale – Option Care Health

• Deliver value to shareholders: Offers $32.05 per share in cash, approximately 37% above the October 5 closing price. Provides a cash exit amid earnings pressure and uncertainty over the company’s recovery.

• Continue under existing management: Keeps Option Care as a separate company with its own management team, with backing to invest in services and technology.

Expert Opinion on Transaction

• J.P. Morgan — Attractive purchase price: Values the deal at 11× expected 2027 adjusted EBITDA, viewing the price as modest given Option Care’s strategic value.

• William Blair — Recent problems explain the lower price: Notes that several similar home-based healthcare businesses sold at higher earnings multiples. Option Care’s patient losses and uncertain recovery help explain the difference. The buyers could benefit if the business improves.

• Evercore — Earnings and distribution upside: Estimates a 0.7% boost to McKesson’s fiscal 2028 earnings per share before operating benefits, assuming an April 2027 closing. Additional distribution business could generate $1.0–$1.5 billion in revenue and $10–$30 million in adjusted operating income.

• UBS — Limited early benefit: Expects McKesson’s first-year earnings to remain broadly unchanged or fall slightly before operating benefits, assuming 50% debt and 50% cash funding.

Option Care Health: Company Overview

Option Care Health (NASDAQ: OPCH) is the largest independent provider of home and alternate-site infusion services in the United States. The company provides specialty pharmaceutical therapies outside traditional hospital settings through an integrated network of pharmacies, infusion facilities, and more than 5,000 clinical professionals.

Business Model and Services

• Chronic Therapies (~75% of Revenue): Recurring infusion treatments for autoimmune diseases, immune deficiencies, neurological conditions, and rare disorders.

• Acute Therapies (~25% of Revenue): Short-term infusion treatments, primarily intravenous antibiotics for serious infections.

• Integrated Care Delivery: Combines pharmaceutical procurement, medication preparation, nursing services, treatment administration, patient monitoring, and insurance authorization.

• Reimbursement Model: Generates revenue through commercial insurers, government healthcare programs, and other payers under negotiated reimbursement arrangements.

Financial Performance

Competitive Positioning

• National operating scale, established hospital and physician referral relationships, and specialized clinical infrastructure.

• Its integrated pharmacy and nursing capabilities enable the administration of complex specialty therapies in patients’ homes and ambulatory infusion centers.

• Benefits from growing specialty pharmaceutical utilization and the continued migration of clinically appropriate infusion treatments from hospitals to lower-cost care settings.

See the detailed Report Below:

Read more

Women’s Health Market Based on Indications

Investor Preferences Across Women’s Health HCIT Segments

• Maternal Health & Postpartum: Integrated EHR and remote monitoring platforms are attracting investment as hospitals and payers seek better care coordination and fewer pregnancy complications. VC favors emerging technologies, while growth equity prioritizes established hospital adoption and payer contracts.

• Fertility & IVF: Specialized EHR, telehealth and Pharma IT platforms benefit from recurring revenue, high switching costs and employer-sponsored fertility benefits. PE favors established platforms with consolidation potential, while VC targets AI-driven embryo analytics and clinical innovation.

• Breast & Gynecological Oncology: High treatment costs increase demand for RCM automation and precision medicine. PE targets profitable billing platforms, while VC and growth equity focus on proprietary genomic data, pharmaceutical customers and recurring analytics revenue.

• Menopause & Midlife: Growing insurance coverage and employer partnerships are creating recurring revenue opportunities for virtual care platforms. VC favors emerging care models, while growth equity seeks proven patient retention and insurance coverage.

• Chronic Gynecological Conditions: Diagnostic delays in PCOS and endometriosis are driving investment in telehealth, AI diagnostics and biomarker research. Early-stage VC focuses on care innovation, while life sciences VC targets proprietary technologies with clinical validation potential.

• Pelvic Health & Incontinence: Home-based rehabilitation and connected monitoring are creating opportunities for digital therapeutics. VC and impact investors favor platforms that improve access, treatment adherence and measurable clinical outcomes.

  Select Private Equity and Venture Capital Portfolio

M&A Transactions in Past 12 Month

See More on the Report Below

Hcit Women's Health Deep Dive Oct 2026

2.21MB ∙ PDF file

Download

Download

Revenue cycle management (RCM) is becoming a larger part of healthcare operations as providers deal with rising administrative costs, staffing shortages, claim denials and pressure on margins. The U.S. RCM market grew from $158.4 billion in 2020 to $234.5 billion in 2025 and is projected to reach $329.8 billion by 2030, with hospitals accounting for roughly 56% of spending.

Market Scope

• Patient Access: Scheduling, registration, eligibility checks, prior authorization and cost estimation; market expected to grow from $2.8B in 2025 to $4.8B by 2030.

• Clinical & Mid-Cycle: Clinical documentation, charge capture, utilization review and medical coding.

• Claims & Clearinghouse: Claims scrubbing, routing, EDI connectivity and payer-status tracking.

• Denials & Revenue Integrity: Denial prevention, appeals, underpayment recovery and receivables management.

• Patient Payments & Managed RCM: Digital billing, payment plans, collections and outsourced end-to-end RCM; outsourced RCM is projected to reach $69.6B by 2030.

Market Trends

• Shift to Preventive RCM: Providers are addressing eligibility, authorization and denial risks earlier in the workflow.

• AI-Led Automation: AI is automating coding, prior authorization, denials and other administrative workflows.

• Growing Outsourcing: Outsourced RCM penetration is expected to increase from 17% to 21% by 2030.

• Platform Consolidation: Health systems are replacing fragmented point solutions with integrated RCM platforms.

• Outcome-Based Pricing: Vendors are increasingly linking fees to collections, denial reduction and A/R improvement.

Evolution of RCM

RCM Market Segments

RCM Platform Consolidations

RCM Revenue Models & Investor Attractiveness Across the Workflow

M&A Transactions in Past 12 Months

See the Full Report Below:

Hcit Revenue Cycle Management Deep Dive

2.33MB ∙ PDF file

Download

Download

Specialty EHRs are evolving beyond documentation systems into broader platforms that combine clinical workflows, administrative functions, financial operations, AI, and data monetization.

Horizontal EHRs are built around standardized, multi-specialty workflows. That model works poorly in areas such as oncology, ophthalmology, gastroenterology, and behavioral health, where providers manage more complex clinical pathways, imaging, procedures, specialty billing, and disease-specific data.

That complexity creates room for vertical software. Specialty EHR vendors can embed themselves more deeply into day-to-day practice operations, creating higher switching costs and stronger opportunities to expand into adjacent products.

Specialty EHRs Are Gaining Share

• Horizontal EHRs leave workflow gaps: Specialty practices need purpose-built clinical, imaging, reporting, and billing workflows that generic systems often cannot support efficiently.

• Administrative complexity drives deeper adoption: Complex coding, reimbursement, registries, imaging, and patient workflows push specialty EHRs beyond recordkeeping into broader operating platforms.

• Fragmentation is driving consolidation: Providers use multiple point solutions across clinical and financial workflows, creating demand for integrated specialty platforms.

Data Is Becoming a Strategic Asset

Specialty EHR vendors also accumulate longitudinal, disease-specific datasets as they become embedded in clinical workflows.

That data can support clinical research, registries, trial matching, RWD/RWE, and life-sciences partnerships, creating an additional monetization layer beyond provider software budgets.

Specialty EHR Market Segments

Select M&A Transactions in Past 12 Months

Revenue Streams & Investor Perspectives

Specialty EHR vendors increasingly use the core EHR as a land product, then expand monetization across higher-value workflows, AI, RCM, payments, and data, increasing ARPU, customer stickiness, and strategic value.

• Core software: EHR SaaS, specialty modules, and practice-management software generate recurring revenue, high gross margins, and strong customer retention.

• AI & automation: Ambient documentation, coding, and clinical decision support create incremental subscription or usage-based revenue while expanding ARPU.

• Financial workflows: RCM, billing, and payments let vendors participate directly in practice economics, with RCM potentially generating 2–7% of collections.

• Data monetization: RWD/RWE licensing opens access to pharma and biotech budgets and can generate 85%+ gross margins.

Please see the detailed report below:

Hcit Monthly Insights August 2026

5.02MB ∙ PDF file

Download

Download

Healthcare IT is entering a more disciplined phase of growth. Artificial intelligence remains the sector’s most visible catalyst, but adoption and investment are increasingly tied to practical outcomes: reducing administrative work, improving clinical productivity, strengthening revenue collection and delivering measurable returns for providers and payers. At the same time, interoperability, cybersecurity, value-based reimbursement and platform consolidation are reshaping how healthcare organizations evaluate technology vendors.

Investment Activity Is Recovering, but Capital Remains Concentrated

M&A activity continues to be driven by strategic buyers and private equity firms seeking broader, end-to-end platforms. Buyers are acquiring point solutions to expand capabilities, enter adjacent markets and accelerate product development, particularly across clinical workflows, revenue cycle management, patient engagement and administrative automation. More disciplined valuations and improved financing conditions are also creating attractive entry points for well-capitalized acquirers.

Venture funding has similarly begun to recover, with U.S. digital health companies raising $7.4 billion during the first half of 2026, compared with $6.4 billion in the first half of 2025. However, the rebound remains highly selective: approximately 45% of H1 2026 funding came from rounds exceeding $100 million. Investors are concentrating capital in companies with commercial traction, clinical validation, defensible technology and a clear ability to demonstrate financial or operational ROI.

Public Markets Continue to Differentiate Between Business Models

Public HCIT performance remains uneven. Over the last 12 months, pharma services companies led the report’s sector indices with a 25% increase, supported by improving biotech funding, greater R&D activity and sustained outsourcing demand. EHR, revenue cycle management and diversified HCIT companies gained approximately 14%, while benefits and telehealth companies rose 9%. Value-based care declined 4%, reflecting continued pressure from medical costs and reimbursement uncertainty.

Valuations also highlight the market’s preference for recurring, high-margin software models. EHR and RCM companies traded at approximately 8.1x LTM revenue, compared with 4.6x for pharma services, 3.3x for benefits and telehealth, and 0.72x for value-based care. The valuation gap reflects differences in revenue predictability, gross margins, capital intensity and exposure to medical-cost risk.

Three Segments Are Defining the Next Phase of HCIT

EHR and PACS platforms are evolving from systems of record into AI-enabled clinical infrastructure. Interoperability mandates, cloud migration, ambient documentation, diagnostic AI and integrated revenue cycle capabilities are expanding the strategic role of these platforms. At the same time, high switching costs and workflow disruption continue to protect established vendors, while hospitals increasingly scrutinize new investments based on total cost of ownership, compliance and margin impact.

Telehealth and virtual care are moving beyond basic video consultations toward more integrated models covering behavioral health, chronic care, remote patient monitoring, specialty care and benefits navigation. Growth is supported by clinician shortages, an aging population and the continued movement of care into the home. However, vendors must increasingly prove cost savings, clinical outcomes and sustained patient engagement rather than relying solely on convenience or access.

Life sciences technology and pharma CRM are being transformed by AI, omnichannel engagement and growing pressure to improve R&D productivity. Commercial platforms are evolving from basic customer databases into intelligent engagement systems that integrate HCP data, prescribing activity, real-world evidence and next-best-action recommendations. Across R&D, demand is rising for eClinical systems, regulatory automation, lab informatics, biosimulation and AI-enabled documentation platforms that can reduce development timelines and improve compliance.

Please open the full report below:

Hcit Monthly Insights August 2026

5.02MB ∙ PDF file

Download

Download

Hcit Monthly Insights July 2026

5.04MB ∙ PDF file

Download

Download

Healthcare IT is moving beyond standalone software toward integrated platforms that control critical clinical, administrative, and commercial workflows. The market increasingly rewards solutions that reduce labor, improve collections, support compliance, and sit directly inside existing systems rather than adding another disconnected tool.

Key Market Themes

M&A remains the primary liquidity route

Transaction activity has remained resilient, but buyers are selective and increasingly focused on RCM, clinical infrastructure, data platforms, and workflow automation. Private equity is targeting scaled control investments, while strategic buyers are using tuck-ins to add AI, diagnostics, and adjacent capabilities.

Venture capital is concentrating around category leaders

Funding has not broadly recovered; capital is rotating toward fewer, higher-conviction companies. Just over 8% of deals captured 45% of invested capital, widening the gap between scaled platforms and subscale vendors.

AI alone is no longer enough

Premium capital is moving toward companies that combine AI with healthcare expertise, proprietary workflow context, deep integrations, and defensible distribution. Buyers increasingly expect measurable financial outcomes rather than broad productivity claims.

Public Market Overview - Last 12 Months

Value-Based Care leads market performance while EHR/RCM lags: Value-Based Care delivered the strongest market cap performance at +36%, reflecting investor preference for cost-containment and outcomes-driven models, while EHR/RCM & Other HCIT declined 35%, signaling continued pressure on traditional HCIT platforms.

Benefits/Telehealth commands the highest EBITDA multiple: Benefits/Telehealth trades at the highest EBITDA multiple at 78x, followed by DTC and Value-Based Care, suggesting investors continue to reward scaled platforms with earnings visibility, recurring demand, and attractive growth profiles.

Revenue multiples remain compressed: Pharma Services is the most resilient, while Value-Based Care trades lower despite stronger share performance.

HCIT Market Niches Covered

EHR & PACS Platforms

EHR and PACS platforms form the core digital infrastructure of hospitals, supporting patient records, clinical documentation, imaging, interoperability, and care coordination.

The market is shifting toward cloud-based, interoperable platforms that combine EHR, imaging, RCM, analytics, and AI-enabled decision support. Regulatory mandates, rising imaging volumes, clinician burnout, and aging populations continue to support demand, while high switching costs strengthen incumbent retention.

Commercial value increasingly depends on integration depth, workflow ownership, implementation discipline, and demonstrable improvements in staffing efficiency or financial performance. Recent M&A and venture activity shows continued appetite for enterprise imaging, clinical AI, and integrated hospital platforms.

Telehealth & Virtual Care

Telehealth has become a permanent part of hybrid care delivery, supporting virtual consultations, behavioral health, chronic disease management, remote monitoring, and care delivered outside traditional facilities.

Growth is moving away from commodity virtual visits toward specialty care, RPM, behavioral health, care navigation, and clinically connected weight-management models. EHR integration, employer ROI requirements, and reimbursement visibility are becoming increasingly important, while standalone DTC models face retention and regulatory pressure.

The strongest commercialization models combine clinical services, recurring contracts, measurable outcomes, and established distribution through employers, payers, providers, pharmacies, or health systems. These characteristics improve retention and make the business more attractive to both strategic acquirers and growth investors.

Life Sciences Tech & Pharma CRM

Life sciences technology supports drug development through clinical-trial software, data management, regulatory systems, lab informatics, and biosimulation, while pharma CRM platforms coordinate compliant engagement with healthcare professionals.

The sector is moving toward AI-enabled R&D, connected laboratories, automated regulatory documentation, omnichannel engagement, and next-best-action tools. CRM re-platforming is also accelerating as Veeva transitions customers to Vault CRM and Salesforce re-enters through Life Sciences Cloud.

Funding and M&A interest is strongest where platforms reduce development timelines, improve trial execution, automate regulated workflows, or connect proprietary scientific and commercial datasets. Large strategic transactions indicate that scaled clinical-research infrastructure and differentiated data assets remain highly valuable.

Please open the full report below:

Hcit Monthly Insights July 2026

5.04MB ∙ PDF file

Download

Download

Please download HCIT Monthly Insights - May 2026 below:

Hcit Monthly Insights May 2026

1.37MB ∙ PDF file

Download

Download